[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

CA3186956A1 - Combination therapy for inhalation administration - Google Patents

Combination therapy for inhalation administration

Info

Publication number
CA3186956A1
CA3186956A1 CA3186956A CA3186956A CA3186956A1 CA 3186956 A1 CA3186956 A1 CA 3186956A1 CA 3186956 A CA3186956 A CA 3186956A CA 3186956 A CA3186956 A CA 3186956A CA 3186956 A1 CA3186956 A1 CA 3186956A1
Authority
CA
Canada
Prior art keywords
solution composition
pharmaceutical solution
composition according
long
soft mist
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3186956A
Other languages
English (en)
French (fr)
Inventor
Alejandro NIETO ORELLANA
Maria Maeso Puertollano
Laura Andrade Benitez
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chemo Research SL
Original Assignee
Chemo Research SL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chemo Research SL filed Critical Chemo Research SL
Publication of CA3186956A1 publication Critical patent/CA3186956A1/en
Pending legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/468-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/47042-Quinolinones, e.g. carbostyril
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pain & Pain Management (AREA)
  • Dispersion Chemistry (AREA)
  • Otolaryngology (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA3186956A 2020-07-31 2021-07-30 Combination therapy for inhalation administration Pending CA3186956A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20382710 2020-07-31
EP20382710.0 2020-07-31
PCT/EP2021/071369 WO2022023515A1 (en) 2020-07-31 2021-07-30 Combination therapy for inhalation administration

Publications (1)

Publication Number Publication Date
CA3186956A1 true CA3186956A1 (en) 2022-02-03

Family

ID=72039503

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3186956A Pending CA3186956A1 (en) 2020-07-31 2021-07-30 Combination therapy for inhalation administration

Country Status (10)

Country Link
US (1) US20230270754A1 (zh)
EP (1) EP4188327A1 (zh)
JP (1) JP2023540171A (zh)
KR (1) KR20230052903A (zh)
CN (1) CN115989032A (zh)
AU (1) AU2021314977A1 (zh)
BR (1) BR112023001689A2 (zh)
CA (1) CA3186956A1 (zh)
MX (1) MX2023001201A (zh)
WO (1) WO2022023515A1 (zh)

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4851317A (en) 1987-11-04 1989-07-25 E. I. Du Pont De Nemours And Company Laminar flow toning station having conductive and nonconductive elements therein
SK282468B6 (sk) 1995-06-27 2002-02-05 Boehringer Ingelheim Kg Farmaceutický prostriedok na výrobu inhalovateľných aerosólov bez obsahu hnacieho plynu a jeho použitie
DE19536902A1 (de) 1995-10-04 1997-04-10 Boehringer Ingelheim Int Vorrichtung zur Hochdruckerzeugung in einem Fluid in Miniaturausführung
DE19653969A1 (de) 1996-12-20 1998-06-25 Boehringer Ingelheim Kg Neue wässrige Arzneimittelzubereitung zur Erzeugung treibgasfreier Aerosole
SK286694B6 (sk) 2000-05-22 2009-03-05 Chiesi Farmaceutici S.P.A. Aerosólový farmaceutický prostriedok
US20020137764A1 (en) 2000-10-31 2002-09-26 Karin Drechsel Inhalable formulation of a solution containing a tiotropium salt
JP2004512359A (ja) 2000-10-31 2004-04-22 ベーリンガー インゲルハイム ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト 抗コリン作用薬及びコルチコステロイドをベースとする新規医薬組成物
US20030055026A1 (en) 2001-04-17 2003-03-20 Dey L.P. Formoterol/steroid bronchodilating compositions and methods of use thereof
EP1879571A1 (de) 2005-04-23 2008-01-23 Boehringer Ingelheim International GmbH Arzneimittelkombination für die inhalation enthaltend neben einem anticholinergikum ein betamimetikum und ein steroid
US20070293460A1 (en) 2005-10-31 2007-12-20 Richie's Pharmacy And Medical Supply, Incorporated Delivery of a combination therapy for asthma and chronic obstructive pulmonary disease
US20070098644A1 (en) 2005-10-31 2007-05-03 Richie's Pharmacy And Medical Supply, Incorporated Delivery of a combination therapy for asthma and chronic obstructive pulmonary disease
DE102006023756A1 (de) 2006-05-20 2007-11-29 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ethanolhaltige Aerosolformulierung für die Inhalation
PE20121467A1 (es) 2009-12-23 2012-11-07 Chiesi Farma Spa Formulacion de aerosol para la enfermedad pulmonar obstructiva cronica
CA2785349C (en) 2009-12-23 2018-07-03 Chiesi Farmaceutici S.P.A. Combination therapy for copd
TWI495468B (zh) 2009-12-23 2015-08-11 Chiesi Farma Spa 治療慢性阻塞性肺病(copd)之醫藥組成物
US20120220557A1 (en) 2011-02-17 2012-08-30 Chiesi Farmaceutici S.P.A. Liquid propellant-free formulation comprising an antimuscarinic drug
EP2934479B1 (en) 2012-12-21 2018-09-19 Boehringer Ingelheim Vetmedica GmbH Ciclesonide for the treatment of airway disease in horses
LT3089735T (lt) 2013-12-30 2018-09-10 Chiesi Farmaceutici S.P.A. Glikopironio bromido ir formoterolio derinio stabili suslėgta aerozolinė tirpalo kompozicija
SI3096737T1 (en) 2013-12-30 2018-07-31 Chiesi Farmaceutici S.P.A. Stable aerosol pressure solution containing glycopyrione bromide and formoterol
US9554992B2 (en) 2014-06-09 2017-01-31 Chiesi Farmaceutici S.P.A. Inhalation particles comprising a combination of an anticholinergic, a corticosteroid and a beta-adrenergic
EP3157522B1 (en) 2014-06-18 2019-09-04 Boehringer Ingelheim Vetmedica GmbH Muscarinic antagonists and combinations thereof for the treatment of airway disease in horses
GB201520862D0 (en) * 2015-11-25 2016-01-13 Jagotec Ag Pharmaceutical composition
US10098837B2 (en) 2016-07-28 2018-10-16 Chiesi Farmaceutici S.P.A. Combination therapy for COPD

Also Published As

Publication number Publication date
BR112023001689A2 (pt) 2023-05-02
JP2023540171A (ja) 2023-09-22
KR20230052903A (ko) 2023-04-20
CN115989032A (zh) 2023-04-18
AU2021314977A1 (en) 2023-03-02
WO2022023515A1 (en) 2022-02-03
MX2023001201A (es) 2023-05-03
EP4188327A1 (en) 2023-06-07
US20230270754A1 (en) 2023-08-31

Similar Documents

Publication Publication Date Title
US11213485B2 (en) Pharmaceutical solution formulations for pressurized metered dose inhalers
EP2201964B1 (en) Formoterol superfine formulation
RU2327450C2 (ru) Фармацевтические продукты и композиции, содержащие специфические антихолинергические средства, агонисты бета-2 и кортикостероиды
US20130074834A1 (en) Pharmaceutical Combinations
EP1415647A1 (en) "Long-acting beta-2 agonists ultrafine formulations"
US20230270754A1 (en) Combination therapy for inhalation administration
JP2014237666A (ja) アルホルモテロール及びチオトロピウムの組成物及びその使用方法